Advertisement
OS
For UK healthcare professionals only
October 2015 Br J Cardiol 2015;22:127–9 doi:10.5837/bjc.2015.033 Online First
Peter Sever
(more…)
September 2014 Br J Cardiol 2014;21:104
BJCardio Staff and others
FH: improving detection in primary care The launch of the NICE (National Institute of Health and Care Excellence) guidelines for familial hypercholesterolaemia (FH) heralded great optimism for improving detection rates in primary care.1 Even with new research showing that FH is more common than previously thought,2 still around 80% of patients are not recognised. Novel detection approaches are clearly needed. Professor Nadeem Qureshi (University of Nottingham) presented preliminary findings from six GP centres taking part in FAMCHOL (Feasibility of Improving Identification of Familial Hypercholesterolaemia in General Practice: Intervention
November 2009 Br J Cardiol 2009;16:295–8
Devaki Nair
Introduction Bile acid sequestrants (BAS) were the first class of lipid-lowering drug to be developed for reducing blood cholesterol levels.1 Now, after their introduction 30 years ago, BAS still continue to command a position in the treatment of hyperlipidaemia.2 How do BAS work? Figure 1. Mode of action of bile acid sequestrants BAS bind to negatively charged bile acids in the intestine and impede their absorption (figure 1). This process depletes the bile acid pool and disrupts the enterohepatic circulation of bile acids, thus, increasing the synthesis of bile acids. Cholesterol is, therefore, diverted to bile acid synthesis, thereby reduc
May 2006 Br J Cardiol 2006;13:196-202
Andrew Davies, John Hutton, John O'donnell, Sarah Kingslake
No content available
January 2006 Br J Cardiol 2006;13:72-6
Alan Middleton, Ahmet Fuat
No content available
July 2004 Br J Cardiol 2004;11:292-9
Andrei C Sposito, Jose Augusto S Barreto-Filho
No content available
March 2004 Br J Cardiol 2004;11:148-55
William Insull Jr, Adrian D Marais, Ronnie Aronson, Sheryl Manfreda, and the Fluvastatin Study Group
No content available
September 2002 Br J Cardiol 2002;9:469-75
Donald B Hunninghake, Michael Davidson, Howard R Knapp, Helmut G Schrott, Sheryl Manfreda, and the Fluvastatin Study Group
No content available
September 2002 Br J Cardiol 2002;9:460-8
Iain Broom, Elixabeth Hughes, Paul Dodson, John Reckless, on behalf of the Orlistat UK Study Group
No content available
For healthcare professionals only
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits